Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Trial Profile

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms GT-20
  • Sponsors ALK-Abello
  • Most Recent Events

    • 16 Oct 2013 Planned End Date changed to 17 Jul 2012.
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top